INGELHEIM, Germany -
- For Healthcare Media Outside the U.S.A., Canada, and Japan
Early secondary prevention with Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA* [25mg]) is at least as effective and safe as initial treatment with ASA 100 mg alone after an ischaemic stroke or transient ischaemic attack (TIA). Results from the EARLY[1] study, presented for the first time at the 13th Congress of the European Federation of Neurological Societies in Florence on 15 September 2009, showed that while functional outcome at 3 months was similar between the two treatment groups there were numerically fewer recurrent ischaemic events in patients who received Aggrenox(R) from the first day after their ischaemic event compared to those patients who received ASA as initial therapy.
“Guidelines recommend administration of ASA as the gold standard for early secondary prevention after ischaemic stroke,” explained Professor Reinhard Dengler, Director of the Neurology Clinic at the Hannover Medical School and Coordinating Investigator of EARLY. “We now have scientifically-based experience with early administration of extended-release dipyridamole plus ASA. EARLY is the first study to have investigated this in a prospective manner.”
EARLY involved more than 250 investigators from 46 stroke units across Germany, who enrolled and treated 543 patients within 24 hours of an ischaemic event. The study is based on the PROBE (prospective, randomized, open-label to treatment blinded to endpoint) design and had two treatment arms:
- 283 patients received Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA [25mg]) twice daily from day 1 to day 90 after an ischaemic stroke or TIA - 260 patients received ASA 100 mg once daily between days one and seven, followed by Aggrenox(R) (extended-release dipyridamole [200 mg] plus ASA [25mg]) twice daily between days 8 and 90.
The primary efficacy outcome (severity of disability) was measured 90 days after the ischaemic event based on a blinded telephone assessment using the Modified Rankin Scale (mRS). After 90 days, 56.4 per cent of patients who received Aggrenox(R) treatment from Day 1 had little or no disability (mRS 0-1) compared with 52.4 per cent of patients in the ASA initial therapy group (odds ratio 0.96; 95% CI: 0.65.-1.42; p = 0.83).
For the combined secondary outcome of vascular and non-vascular death, non-fatal stroke, TIA, non-fatal myocardial infarction and bleeding complications, EARLY showed that there were numerically fewer events with early administration of Aggrenox(R) compared with ASA (hazard ratio [HR]: 0.7; 95% CI: 0.41-1.19; p = 0.19). The relative risk of a relevant outcome was 30 per cent lower in the early Aggrenox(R) therapy group (28 patients; 9.9 per cent) than in the ASA initial therapy group (38 patients; 14.6 per cent). The difference in the occurrence of non-fatal stroke and TIA was particularly marked, with 32 events (12.3 per cent) in the ASA initial therapy group compared with 20 (7.1 per cent) in the early Aggrenox(R) therapy group (HR: 0.63; 95% CI: 0.34-1.14; p = 0.12). Although not statistically significant, these data in favour of initial therapy with Aggrenox(R) are consistent with the results of the ESPS-2[2] and ESPRIT[3] studies, which showed treatment with the extended-release dipyridamole /ASA combination to be safe and superior to treatment with ASA alone.
“Although the trend in favour of early initiation of Aggrenox(R) is not significant, we see biological pointers which indicate a benefit,” explained Prof. Dengler.
Safety data from EARLY indicate that initial therapy with Aggrenox(R) was as safe as initial treatment with ASA, with respect to serious adverse events and deaths. In patients who received early initiation with Aggrenox(R) there was an increased incidence of headache and gastrointestinal complaints
“EARLY has shown that early initiation of therapy with extended-release dipyridamole plus ASA is at least as safe and effective as early initiation of treatment with ASA alone,” said Prof. Dengler.
Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This press release is not intended for distribution within the U.S.A.
Notes to Editor:
*ASA = acetylsalicylic acid (Aspirin(R))
Modified Rankin Scale
The Modified Rankin Scale is a numerical functional assessment scale used to rank levels of disability after stroke. Patients receive a score between 0 and 6, where 0 represents no symptoms at all and higher scores represent increasingly severe disability.[4]
About ESPS-2
In the ESPS-2 study it was shown that the combination of low dose aspirin plus extended-release dipyridamole (marketed as Aggrenox(R) and Asasantin Retard(R)) reduced the risk of recurrent stroke by 37 precent compared to placebo. Stroke risk was reduced by 18.1% in the aspirin-alone group.[2]
About ESPRIT
The ESPRIT trial compared a combination of ASA and dipyridamole with ASA alone. The majority of patients on the combination received a free combination of ASA and extended-release dipyridamole (200mg twice daily); 8 percent of the patients received the fixed-dose combination (200mg extended-release dipyridamole plus 25 mg ASA twice daily, as marketed as Aggrenox(R) and Asasantin(R) Retard). Free ASA dosages varied from 30 to 325mg/day.[3]
About Aggrenox(R)
Aggrenox(R) (marketed as Aggrenox(R) and as Asasantin(R) Retard) is an antiplatelet agent that combines extended release dipyridamole and ASA. A product of Boehringer Ingelheim’s research and development, it is indicated for the prevention of recurrent stroke and transient ischaemic attack (TIA).[5]
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees. Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.com.
For related media information please click here: www.boehringer-ingelheim.com/corporate/news/information_packs/acutestroke.asp
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the space if one exists.)
References 1. Dengler R et al. Early treatment of Aspirin and Extended-Release Dipyridamole versus Aspirin alone for treatment of Minor Ischaemic Stroke within 24 hour of stroke-onset (EARLY-Trial): a randomised, open-labelled, blinded-endpoint trial. Eur J Neurol 2009 (Suppl). 2. Diener HC et al. European Stroke Prevention Study 2: Efficacy and Safety data. J Neurol Sci 1997: 151 (Suppl); 1-77 3. ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT). Lancet 2006: 367; 1665-1673 4. Modified Rankin Scale. Internet Stroke Center. Available at www.strokecenter.org/trials/scales/rankin.html Accessed 7 September 2009 5. Summary of product characteristics. Asasantin Retard(R). Electronic medicines compendium. emc.medicines.org.uk Accessed 7 September 2009
Source: Boehringer Ingelheim
Contact: John Pugh, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, E-mail: press at boehringer-ingelheim.com
Related Press Releases
Amnis' advice on acute care: the transfer of care process is key September 29th, 2009 Patients who tie up acute care beds but who might be better treated in a community setting create an additional 'organisational cork' on the effective flow of patients through hospitals claims the specialist healthcare quality, innovation and productivity improvement enabler, Amnis. A recent study, carried out over 16 weeks, identified over 1,500 days in one NHS Trust alone when acute beds were occupied by patients who would have been better off in a sub-acute setting.
D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)August 16th, 2009 REHOVOT, Israel - D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company's late stage clinical stroke program. The financial round combined a rights offering of NIS 57 million and an Initial Public Offering (IPO) of NIS 28 million.
Glybera(TM) Shows Long-Term Health BenefitsJune 17th, 2009 AMSTERDAM, The Netherlands - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today new data showing that a one-time administration of its lead product GlyberaTM results in significant long-term health benefits. Long-term follow-up data from two clinical trials show that one administration with GlyberaTM brings significant and clinically important reduction in acute pancreatitis in lipoprotein lipase deficient patients.
AF AWARE Cardiology Groups Call for Greater Awareness and Better Education on Atrial FibrillationJune 7th, 2009 LONDON - Survey Shows Many Doctors Find the Management of Atrial Fibrillation Difficult and Patients are Unaware of the Risks, Complexities and Treatment for This Most Common of Heart Rhythm Disorders
Four leading patient and medical associations announced today the formation of AF AWARE (Atrial Fibrillation AWareness And Risk Education), a joint initiative to highlight and address issues that contribute to the growing burden of atrial fibrillation (AF) worldwide. AF is a common yet under-recognised and poorly understood abnormal heart rhythm that is associated with poor quality of life, substantial numbers of hospitalisations, increased risk of severe and potentially fatal cardiovascular complications such as stroke, as well as death.
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non Hodgkin's Lymphoma PatientsJune 4th, 2009 BERLIN, Germany - Single Dose Palonosetron is Effective and Safe in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Aggressive Non-Hodgkin's Lymphomas who Undergo Moderately Emetogenic Chemotherapy
- Data Presented Today at the European Haematology Association Congress in Berlin, Germany
New data presented today at the EHA (European Haematology Association) Congress in Berlin show that a single dose of palonosetron, a second generation 5-HT3 receptor antagonist, is effective and safe in preventing chemotherapy-induced nausea and vomiting (CINV) in patients with aggressive non Hodgkin's lymphoma (NHL), treated with cytotoxic agents. The result comes from a study conducted in Italy on behalf of the Italian Group of Study on Lymphomas (GISL) by a multicentric team coordinated by Dr.
Heart Disease Treatment BreakthroughMay 31st, 2009 GATESHEAD, England - A leading GP has welcomed the launch of a potentially revolutionary heart disease treatment that offers people around the world the hope of combating the killer disease. GP Dr Rob Hicks said the launch of Ateronon, the natural supplement developed by Cambridge scientists, was a huge breakthrough in the treatment of heart disease related illnesses that can cause heart attacks and stroke.
Boehringer Ingelheim and the World Stroke Organization Announce Partnership in the World Stroke AcademyMay 26th, 2009 INGELHEIM, Germany - For Healthcare Media Outside the U.S.A., Canada, and Japan
Boehringer Ingelheim announced today that it will become the founding sponsor of the World Stroke Academy, a novel training initiative for stroke professionals being developed by the World Stroke Organization (WSO). This latest educational initiative from the WSO will bring together an international group of stroke experts - led by Professor Michael Brainin of the Danube University Krems, Austria - to provide information about stroke and knowledge for health professionals and medical doctors in order to improve prevention, therapy and management of stroke.
D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke PatientsMay 5th, 2009 REHOVOT, Israel - D-Pharm announced today that it has submitted IND and Special Protocol Assessment (SPA) packages to the US Food and Drug Administration (FDA), for its pivotal Phase III clinical trial of DP-b99 in acute ischemic stroke patients. D-Pharm plans to initiate the trial later this year following FDA review of the IND and SPA.
PhotoThera Closes US$50 Million Financing, Announces New President and Chief Executive OfficerApril 29th, 2009 CARLSBAD, California - PREPARES FOR LAUNCH OF 'NEST-3' ACUTE ISCHEMIC STROKE CLINICAL TRIAL
PhotoThera, Inc., the developer of transcranial laser therapy (TLT) designed for the treatment of acute ischemic stroke within 24 hours of stroke onset, announced today that it has closed a US$50 million Series D round of financing led by Warburg Pincus, a leading global private equity firm, to fund a planned follow-on phase III 'NEST-3' (NeuroThera(R) Effectiveness and Safety Trial) clinical study. The Company previously announced that NEST-3 would build upon the results of its NEST-2 trial, which revealed a statistically significant treatment effect for patients with moderate to moderately severe ischemic strokes using a post-hoc data analysis.
Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare AwardsApril 20th, 2009 SINGAPORE - Moleac has been named the Singapore Entrepreneurial Company of the Year, by Frost & Sullivan. This award recognizes companies that have pushed the boundaries of excellence in the healthcare industry and acknowledges Moleac's outstanding performance in 2008.
Related News
New drug shows promise to reduce stroke riskAugust 31st, 2009 LONDON - A new drug developed as an alternative to popular drug warfarin, also used as rat poison, has been found to significantly reduce stroke risk. Generally, patients at risk of stroke are given warfarin to prevent blood clotting, but the treatment is risky and requires regular monitoring.
Second stroke follows first one within hoursJune 2nd, 2009 WASHINGTON - Half of mini-strokes lead to major stroke within 24 hours of the first event, a new research has found. The research has been published in the June 2, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.
Researchers use stroke patient's own stem cells for first timeApril 16th, 2009 WASHINGTON - A stroke patient intravenously received his own bone marrow stem cells, as part of a new research trial in the US. Roland Henrich, 61, was transferred to Memorial Hermann, Texas University Medical Centre (TUMC) on March 25 after suffering a stroke on his farm in Liberty.
Lowered HRT use may have led to fewer heart attacks in womenApril 25th, 2009 WASHINGTON - With decline in the use of hormone replacement therapy (HRT) to treat menopause symptoms, the rate of myocardial infarctions, or heart attacks, has also dropped, a new study has found. However, there has been no decrease in the rate of strokes, the study published in the May issue of the journal Medical Care noted.
Statins cut stroke risk by a fifthApril 15th, 2009 LONDON - Cholesterol-lowering statins can decrease the risk of strokes by about a fifth, a new study has claimed. The research reviewed some 24 studies, and found lower cholesterol levels were associated with a reduced risk of stroke.
Wife of Astor's 85-year-old son says husband suffered mild stroke 2 weeks agoJune 23rd, 2009 Wife: Astor's 85-year-old son had mild strokeNEW YORK — The wife of Brooke Astor's son, Anthony Marshall, says her husband suffered a mild stroke two weeks ago. Charlene Marshall disclosed the stroke Monday outside the courtroom where her husband is on trial on charges of looting his late mother's $198 million estate.
Aspirin improves survival in women with heart diseaseMarch 16th, 2009 WASHINGTON - Researchers have come by additional evidence that aspirin seems to reduce the risk of death in women who have heart disease or have had a stroke. The new study also provides fresh insight into aspirin dosing for women, suggesting that a lower dose of aspirin (81 mg) is as effective as a higher dose (325 mg).
Painkiller oxycodone helps reduce shingles painMarch 31st, 2009 WASHINGTON - A commonly used painkiller has been found to be effective against treating the acute pain of shingles, an illness that often causes severe pain along with a rash. The painkiller oxycodone can help in treating acute pain of shingles, which is caused by reactivation of the varicella zoster virus, a bug that causes chicken pox.
Drinking coffee can lower stroke risk for womenApril 13th, 2009 BOSTON/BERLIN - Women who enjoy drinking coffee may be lowering their risk of suffering a stroke, a new study suggests. Women who drank five to seven cups of coffee a week were 12 percent less likely to have a stroke than were those who downed just one cup a month, the study among 83,000 American women revealed.
Dysport shown to be safe, effective anti-wrinkle treatmentAugust 3rd, 2009 WASHINGTON - A new study has shown that the new anti-wrinkle facial filler Dysport, which could be used as an alternative to Botox, is safe as well as effective. "Our study confirmed that Dysport (abobotulinumtoxinA) is a safe and effective tool in fighting wrinkles," said Dr.
